Related Experiment Video
Updated: Dec 12, 2025

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
Published on: November 9, 2016
[How does a new medicine reach the patient?]
B J Visser1, D A Korevaar2, M M Mokhles3
1Amsterdam UMC, locatie AMC, afd. Interne Geneeskunde, Amsterdam (tevens: lid Jong CBG).
The Medicines Evaluation Board (MEB) in the Netherlands ensures drug safety and efficacy through rigorous quality evaluation and risk-benefit assessment for market authorization. Post-authorization, the MEB actively monitors medicines via pharmacovigilance and manages product information.
Area of Science:
- Medicinal product regulation
- Pharmacovigilance
- Drug safety and efficacy evaluation
Background:
- The Medicines Evaluation Board (MEB) is responsible for granting market authorization for medicinal products within the Netherlands.
- The European Medicines Agency (EMA) oversees the evaluation and safety of medicines across the European Union.
- MEB's primary role involves assessing the quality and the risk-benefit profile of new medicinal products.
Purpose of the Study:
- To outline the regulatory processes and responsibilities of the Medicines Evaluation Board (MEB) in the Netherlands.
- To detail the procedures for obtaining marketing authorization for medicinal products.
- To describe the post-authorization surveillance and information management conducted by the MEB.
Main Methods:
- The MEB evaluates medicinal product quality and the risk-efficacy balance.
- Manufacturers can follow national, decentralized/mutual recognition, or centralized procedures for authorization.
- Pharmacovigilance is maintained post-authorization in collaboration with partners like the Netherlands Pharmacovigilance Centre (Lareb).
Main Results:
- The MEB ensures that only quality-assured medicinal products with a favorable risk-efficacy balance are authorized.
- Three distinct procedures (national, decentralized/mutual recognition, centralized) are available for manufacturers seeking market authorization.
- The MEB actively manages pharmacovigilance, including determining package leaflet text, packaging, and Summary of Product Characteristics (SmPC), and reviewing manufacturer-issued warnings.
Conclusions:
- The MEB plays a critical role in safeguarding public health by ensuring the quality, safety, and efficacy of medicinal products in the Netherlands.
- The established procedures facilitate market access while maintaining stringent regulatory oversight.
- Continuous pharmacovigilance and accurate product information management are integral to the MEB's function in protecting patients.
Related Concept Videos
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug Delivery: Overview
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Clinical Trials: Overview
Routes of Drug Administration: Overview
Enteral administration refers to drugs absorbed through the gastrointestinal tract. They can be swallowed (perorally), placed under the tongue (sublingually), or on the inner lining of the cheeks (buccally). Perorally administered drugs take time to be absorbed and have a slower onset of action. The rectal route is another form of enteral administration, which allows for...
Biopharmaceutics and Pharmacokinetics: Overview

